<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; challenge</title>
	<atom:link href="http://www.tapanray.in/tag/challenge/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>The Indian Drug Industry’s Looming Talent Crisis &#8211; A Recent Landscape</title>
		<link>http://www.tapanray.in/the-indian-drug-industrys-looming-talent-crisis-a-recent-landscape/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=the-indian-drug-industrys-looming-talent-crisis-a-recent-landscape</link>
		<comments>http://www.tapanray.in/the-indian-drug-industrys-looming-talent-crisis-a-recent-landscape/#comments</comments>
		<pubDate>Thu, 18 Jul 2024 07:41:08 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[academia]]></category>
		<category><![CDATA[Academic]]></category>
		<category><![CDATA[challenge]]></category>
		<category><![CDATA[collaboration]]></category>
		<category><![CDATA[competition]]></category>
		<category><![CDATA[crisis]]></category>
		<category><![CDATA[Diversity]]></category>
		<category><![CDATA[great]]></category>
		<category><![CDATA[IMPACT]]></category>
		<category><![CDATA[inclusion]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Indian]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[looming]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[re-skilling]]></category>
		<category><![CDATA[resignation]]></category>
		<category><![CDATA[shortage]]></category>
		<category><![CDATA[skill]]></category>
		<category><![CDATA[talent]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[up-skilling]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10869</guid>
		<description><![CDATA[India&#8217;s pharmaceutical industry, a global generics and drug manufacturing powerhouse, is facing a critical talent deficit. The shortage of skilled professionals is impeding innovation, drug development, and the industry&#8217;s overall competitiveness. This challenge, exacerbated by recent industry dynamics, demands immediate &#8230; <a href="http://www.tapanray.in/the-indian-drug-industrys-looming-talent-crisis-a-recent-landscape/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/the-indian-drug-industrys-looming-talent-crisis-a-recent-landscape/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Pharma Leadership Challenge In Post Covid Paradigm</title>
		<link>http://www.tapanray.in/pharma-leadership-challenge-in-post-covid-paradigm/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=pharma-leadership-challenge-in-post-covid-paradigm</link>
		<comments>http://www.tapanray.in/pharma-leadership-challenge-in-post-covid-paradigm/#comments</comments>
		<pubDate>Mon, 03 Oct 2022 00:00:29 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[challenge]]></category>
		<category><![CDATA[company]]></category>
		<category><![CDATA[customer]]></category>
		<category><![CDATA[digital]]></category>
		<category><![CDATA[digitally]]></category>
		<category><![CDATA[employee]]></category>
		<category><![CDATA[engagement]]></category>
		<category><![CDATA[field]]></category>
		<category><![CDATA[focussed]]></category>
		<category><![CDATA[force]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[leadership]]></category>
		<category><![CDATA[mode]]></category>
		<category><![CDATA[online]]></category>
		<category><![CDATA[organization]]></category>
		<category><![CDATA[paradigm]]></category>
		<category><![CDATA[post covid]]></category>
		<category><![CDATA[pre]]></category>
		<category><![CDATA[presence]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[savvy]]></category>
		<category><![CDATA[share of voice]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[working]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10713</guid>
		<description><![CDATA[Bringing a long cherished relief to many, on September 15, 2022, the World Health Organization said, &#8216;we can see the Finish Line&#8217; for the COVID-19 pandemic but it&#8217;s not over yet’. As I see today, several things are changing pretty fast &#8230; <a href="http://www.tapanray.in/pharma-leadership-challenge-in-post-covid-paradigm/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/pharma-leadership-challenge-in-post-covid-paradigm/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Physicians’ Increasing Digital Proficiency And Its Implication</title>
		<link>http://www.tapanray.in/physicians-increasing-digital-proficiency-and-its-implication/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=physicians-increasing-digital-proficiency-and-its-implication</link>
		<comments>http://www.tapanray.in/physicians-increasing-digital-proficiency-and-its-implication/#comments</comments>
		<pubDate>Mon, 07 Feb 2022 00:00:20 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Biotech]]></category>
		<category><![CDATA[challenge]]></category>
		<category><![CDATA[Covid]]></category>
		<category><![CDATA[COVID-19]]></category>
		<category><![CDATA[customer]]></category>
		<category><![CDATA[Delta]]></category>
		<category><![CDATA[digital]]></category>
		<category><![CDATA[engagement]]></category>
		<category><![CDATA[engaging]]></category>
		<category><![CDATA[HCPs]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Implication]]></category>
		<category><![CDATA[Increasing]]></category>
		<category><![CDATA[New]]></category>
		<category><![CDATA[normal]]></category>
		<category><![CDATA[Old]]></category>
		<category><![CDATA[Omicron]]></category>
		<category><![CDATA[pandemic]]></category>
		<category><![CDATA[physicians]]></category>
		<category><![CDATA[proficiency]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[research]]></category>
		<category><![CDATA[saviness]]></category>
		<category><![CDATA[savvy]]></category>
		<category><![CDATA[study]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[vaccines]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10650</guid>
		<description><![CDATA[At a time, when an unexpected and unprecedented Covid-19 pandemic struck a catastrophic impact on human lives, livelihood, and the global economy the healthcare sector continued surging ahead. This is being fueled by exponential advances in medical science, and the &#8230; <a href="http://www.tapanray.in/physicians-increasing-digital-proficiency-and-its-implication/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/physicians-increasing-digital-proficiency-and-its-implication/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Covid Vaccine Challenges – Abidance To Defined Health Norms Stays As Lifeguard</title>
		<link>http://www.tapanray.in/covid-vaccine-challenges-abidance-to-defined-health-norms-stays-as-lifeguard/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=covid-vaccine-challenges-abidance-to-defined-health-norms-stays-as-lifeguard</link>
		<comments>http://www.tapanray.in/covid-vaccine-challenges-abidance-to-defined-health-norms-stays-as-lifeguard/#comments</comments>
		<pubDate>Mon, 16 Nov 2020 00:00:08 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Abidance]]></category>
		<category><![CDATA[challenge]]></category>
		<category><![CDATA[Challenges]]></category>
		<category><![CDATA[cold-chain]]></category>
		<category><![CDATA[Coronavirus]]></category>
		<category><![CDATA[Covid]]></category>
		<category><![CDATA[COVID-19]]></category>
		<category><![CDATA[distribution]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[immunization]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[logistics]]></category>
		<category><![CDATA[norms]]></category>
		<category><![CDATA[program]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[UIP]]></category>
		<category><![CDATA[Universal]]></category>
		<category><![CDATA[vaccination]]></category>
		<category><![CDATA[Vaccine]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10327</guid>
		<description><![CDATA[There isn’t even a shade of doubt today that Covid-vaccines are coming. However, some critical questions in this area continue to hang in the air, and are expected to remain so for some more time. Thus, every news on the &#8230; <a href="http://www.tapanray.in/covid-vaccine-challenges-abidance-to-defined-health-norms-stays-as-lifeguard/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/covid-vaccine-challenges-abidance-to-defined-health-norms-stays-as-lifeguard/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Covid Prompts Pharma To Move Away From Competition Driven Business Model</title>
		<link>http://www.tapanray.in/covid-prompts-pharma-to-move-away-from-competition-driven-business-model/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=covid-prompts-pharma-to-move-away-from-competition-driven-business-model</link>
		<comments>http://www.tapanray.in/covid-prompts-pharma-to-move-away-from-competition-driven-business-model/#comments</comments>
		<pubDate>Mon, 26 Oct 2020 00:00:16 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[beyond]]></category>
		<category><![CDATA[Business]]></category>
		<category><![CDATA[challenge]]></category>
		<category><![CDATA[Collaborative]]></category>
		<category><![CDATA[companies]]></category>
		<category><![CDATA[competition]]></category>
		<category><![CDATA[Coronavirus]]></category>
		<category><![CDATA[Covid]]></category>
		<category><![CDATA[driven]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[dying]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Leveraging]]></category>
		<category><![CDATA[model]]></category>
		<category><![CDATA[opportunity]]></category>
		<category><![CDATA[pandemic]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[Players]]></category>
		<category><![CDATA[profit]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[self-serving]]></category>
		<category><![CDATA[solo]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[trademark]]></category>
		<category><![CDATA[Vaccine]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10304</guid>
		<description><![CDATA[As deliberated in my just previous article in this blog, Covid has been a watershed in several areas of pharma business. One such key area is its competition driven strategic business model. It aims to deliver significant value for a &#8230; <a href="http://www.tapanray.in/covid-prompts-pharma-to-move-away-from-competition-driven-business-model/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/covid-prompts-pharma-to-move-away-from-competition-driven-business-model/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Pharma’s Dual Challenge &#8211; To Save Lives And Livelihood</title>
		<link>http://www.tapanray.in/pharmas-dual-challenge-to-save-lives-and-livelihood/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=pharmas-dual-challenge-to-save-lives-and-livelihood</link>
		<comments>http://www.tapanray.in/pharmas-dual-challenge-to-save-lives-and-livelihood/#comments</comments>
		<pubDate>Mon, 29 Jun 2020 00:00:05 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[challenge]]></category>
		<category><![CDATA[Clinical]]></category>
		<category><![CDATA[comparative]]></category>
		<category><![CDATA[Coronavirus]]></category>
		<category><![CDATA[Cost]]></category>
		<category><![CDATA[COVID-19]]></category>
		<category><![CDATA[DCGI]]></category>
		<category><![CDATA[dexamethasone]]></category>
		<category><![CDATA[dual]]></category>
		<category><![CDATA[efficacy]]></category>
		<category><![CDATA[favipiravir]]></category>
		<category><![CDATA[herd]]></category>
		<category><![CDATA[immunity]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[population]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[remdesivir]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[treatment]]></category>
		<category><![CDATA[vaccine-induced]]></category>
		<category><![CDATA[Vulnerable]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10146</guid>
		<description><![CDATA[“Jaan hai to jahan hai” (If you have life, you have the world). Prime Minister Modi - with a skillful tweak, used the couplet of the 18th century poet - Mir Taqi Mir, while announcing the criticality of 21-day national lockdown from March 24, 2020 due &#8230; <a href="http://www.tapanray.in/pharmas-dual-challenge-to-save-lives-and-livelihood/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/pharmas-dual-challenge-to-save-lives-and-livelihood/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Organic and Inorganic Growth Strategy For Sustainable Business Excellence</title>
		<link>http://www.tapanray.in/organic-and-inorganic-growth-strategy-for-sustainable-business-excellence/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=organic-and-inorganic-growth-strategy-for-sustainable-business-excellence</link>
		<comments>http://www.tapanray.in/organic-and-inorganic-growth-strategy-for-sustainable-business-excellence/#comments</comments>
		<pubDate>Mon, 30 Apr 2018 00:00:10 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Business]]></category>
		<category><![CDATA[CEO]]></category>
		<category><![CDATA[challenge]]></category>
		<category><![CDATA[growth]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[inorganic]]></category>
		<category><![CDATA[leader]]></category>
		<category><![CDATA[leadership]]></category>
		<category><![CDATA[M&A]]></category>
		<category><![CDATA[management]]></category>
		<category><![CDATA[Novo Nordisk]]></category>
		<category><![CDATA[organic]]></category>
		<category><![CDATA[performance]]></category>
		<category><![CDATA[Pfizer]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[strategy]]></category>
		<category><![CDATA[sustainable]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=8936</guid>
		<description><![CDATA[For an enthusiast, witnessing any organization growing consistently, is indeed exhilarating. This becomes even more interesting at a time when challenges and frequent surprises in the business environment become a new normal. A robust short, medium and long growth strategy &#8230; <a href="http://www.tapanray.in/organic-and-inorganic-growth-strategy-for-sustainable-business-excellence/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/organic-and-inorganic-growth-strategy-for-sustainable-business-excellence/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Draft Pharma Policy 2017 Ticks The Right Boxes: A Challenge Still Remains</title>
		<link>http://www.tapanray.in/draft-pharma-policy-2017-ticks-the-right-boxes-a-challenge-still-remains/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=draft-pharma-policy-2017-ticks-the-right-boxes-a-challenge-still-remains</link>
		<comments>http://www.tapanray.in/draft-pharma-policy-2017-ticks-the-right-boxes-a-challenge-still-remains/#comments</comments>
		<pubDate>Mon, 04 Sep 2017 00:00:12 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[2017]]></category>
		<category><![CDATA[Bank]]></category>
		<category><![CDATA[Boxes]]></category>
		<category><![CDATA[challenge]]></category>
		<category><![CDATA[DoP]]></category>
		<category><![CDATA[Draft]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[GLP]]></category>
		<category><![CDATA[GMP]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[mandatory]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[Policy]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[right]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[ticks]]></category>
		<category><![CDATA[UCPMP]]></category>
		<category><![CDATA[World]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=8396</guid>
		<description><![CDATA[Pharma policy is not a panacea to address all related issues, neither for the patients nor the industry, in general. As I see it, it’s no more than a critical cog in the wheel of the overall macro and the &#8230; <a href="http://www.tapanray.in/draft-pharma-policy-2017-ticks-the-right-boxes-a-challenge-still-remains/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/draft-pharma-policy-2017-ticks-the-right-boxes-a-challenge-still-remains/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Gilead: Caught Between A Rock And A Hard Place In India</title>
		<link>http://www.tapanray.in/gilead-caught-between-a-rock-and-a-hard-place-in-india/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=gilead-caught-between-a-rock-and-a-hard-place-in-india</link>
		<comments>http://www.tapanray.in/gilead-caught-between-a-rock-and-a-hard-place-in-india/#comments</comments>
		<pubDate>Mon, 22 Sep 2014 00:00:51 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[2005]]></category>
		<category><![CDATA[Act]]></category>
		<category><![CDATA[Alliance]]></category>
		<category><![CDATA[Between. Rock]]></category>
		<category><![CDATA[Cadila Healthcare]]></category>
		<category><![CDATA[Caught]]></category>
		<category><![CDATA[challenge]]></category>
		<category><![CDATA[Cipla]]></category>
		<category><![CDATA[CL]]></category>
		<category><![CDATA[Compulsory]]></category>
		<category><![CDATA[Gilead]]></category>
		<category><![CDATA[hamied]]></category>
		<category><![CDATA[hard]]></category>
		<category><![CDATA[Hepatitis C]]></category>
		<category><![CDATA[Hetero labs and Sequent Scientific]]></category>
		<category><![CDATA[HIV/AIDS]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[IPA]]></category>
		<category><![CDATA[IPO. Indian]]></category>
		<category><![CDATA[License]]></category>
		<category><![CDATA[monopolies]]></category>
		<category><![CDATA[Mylan]]></category>
		<category><![CDATA[Office]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[Place]]></category>
		<category><![CDATA[Pricing]]></category>
		<category><![CDATA[Ranbaxy]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[sofosbuvir]]></category>
		<category><![CDATA[Sovaldi]]></category>
		<category><![CDATA[Strides Arcolab]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[tenofovir]]></category>
		<category><![CDATA[Voluntary]]></category>
		<category><![CDATA[yusuf]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=6001</guid>
		<description><![CDATA[I had mentioned in my blog post of August 4, 2014, titled “Hepatitis C: A Silent, Deadly Disease: Treatment beyond reach of Most Indians” that in line with Gilead’s past approach to its HIV medicines, the company would offer to &#8230; <a href="http://www.tapanray.in/gilead-caught-between-a-rock-and-a-hard-place-in-india/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/gilead-caught-between-a-rock-and-a-hard-place-in-india/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Leading Through The Challenge Of Change: Is Pharma Leadership Too Archaic?</title>
		<link>http://www.tapanray.in/leading-through-the-challenge-of-change-is-pharma-leadership-too-archaic/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=leading-through-the-challenge-of-change-is-pharma-leadership-too-archaic</link>
		<comments>http://www.tapanray.in/leading-through-the-challenge-of-change-is-pharma-leadership-too-archaic/#comments</comments>
		<pubDate>Mon, 16 Jun 2014 00:00:39 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[affordable]]></category>
		<category><![CDATA[archaic]]></category>
		<category><![CDATA[Bayer]]></category>
		<category><![CDATA[CEO]]></category>
		<category><![CDATA[challenge]]></category>
		<category><![CDATA[Change]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[eclectic]]></category>
		<category><![CDATA[Gilead]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[inclusive]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[leadership]]></category>
		<category><![CDATA[Michael]]></category>
		<category><![CDATA[mode]]></category>
		<category><![CDATA[Motors]]></category>
		<category><![CDATA[Ostrich]]></category>
		<category><![CDATA[owner]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[PhRMA]]></category>
		<category><![CDATA[promoter]]></category>
		<category><![CDATA[prontosil]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Rsy]]></category>
		<category><![CDATA[Sanofi]]></category>
		<category><![CDATA[Soman.]]></category>
		<category><![CDATA[Sovaldi]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tesla]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=5512</guid>
		<description><![CDATA[A recent major global survey titled “Testing The Health Of The Pharmaceutical Industry” has revealed that a sizable majority of executives polled, though believe the sector is in good shape, are concerned of its reputation. Interestingly, 73 percent of respondents believe &#8230; <a href="http://www.tapanray.in/leading-through-the-challenge-of-change-is-pharma-leadership-too-archaic/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/leading-through-the-challenge-of-change-is-pharma-leadership-too-archaic/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
